Subject Pre-Screening & Authentication
Clinilabs Drug Development Corporation phase 1 units are distinguished from other research facilities by virtue of established methods to pre-screen and authenticate subjects.
Our pre-screening process engages subjects in a large-scale database project. This project enables us to obtain medical history, height, weight, body mass index (BMI) and medication history, and perform routine tests such as a urine drug screen. This information is entered, with permission, into our subject database. Therefore, sponsors are assured that study candidates are pre-screened for eligibility in their studies, minimizing the rate of screen failures.
Subjects also go through a thorough subject authentication process in order to exclude individuals who may be screening at another location, enrolled in another study, or in a lockout period. We have taken steps to minimize the risk of “dual enrollers” and other individuals who may jeopardize study integrity. More than 11 percent of subjects in the U.S. provide false information to investigator sites in order to gain enrollment into a clinical trial or to avoid taxes on research subject stipends. Sponsors have the confidence that these subjects are excluded at Clinilabs research facilities.
I must say, I spend a lot of my time these days trying to persuade people that controlled trials are the only way to get information that’s reliable about drugs.
Good information is the best medicine.
The pace of discovery is going unbelievably fast.
Without drugs, physicians would struggle to find relevance, and patients would suffer without hope.
All truths are easy to understand once they are discovered; the point is to discover them.
I have no ideology. My ideology is health.
If you think compliance is expensive, try non-compliance.
The cures we want aren’t going to fall from the sky. We have to get ladders and climb up and get them.
Advances in drug development have led to greater improvement in the quality of human life than advances in all other fields combined.
One never notices what has been done; one can only see what remains to be done.
I trust I may be enabled in the treatment of patients always to act with a single eye to their good.
I am not accustomed to saying anything with certainty after only one or two observations.
Remember the Three Princes of Serendip who went out looking for treasure? They didn’t find what they were looking for, but they kept finding things just as valuable. That’s serendipity, and our business [drugs] is full of it.
The greatest joy in life is to accomplish. It is the getting, not the having. It is the giving, not the keeping.
There is so much more to be done; the patients are waiting.
The best way to predict the future is to invent it.
Let me tell you the secret that has led me to my goal. My strength lies solely in my tenacity.
Drugs don’t work in patients who don’t take them.
The reward for work well done is the opportunity to do more.
One sometimes finds what one is not looking for.
It is easy to get a thousand prescriptions, but hard to get one single remedy.